Webb26 feb. 2024 · T-DM1 was approved for the adjuvant therapy of HER2+ early BC not in pathological complete response after taxanes + anti-HER2 neoadjuvant therapy. • A phase III randomised trial revealed an increased 3-year invasive disease-free survival rate in patients receiving T-DM1 compared with trastuzumab. • Webb14 feb. 2024 · Conclusions: Among patients with HER2-positive early breast cancer who had residual invasive disease after completion of neoadjuvant therapy, the risk of …
The EMA review of trastuzumab emtansine (T-DM1) for the …
Webb18 juli 2024 · Introduction. The current standard of care for the first-line treatment of human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer (MBC) is a combination regimen comprising the HER2-targeted monoclonal antibodies trastuzumab and pertuzumab plus a taxane. 1-3 The antibody-drug conjugate trastuzumab … Webb26 maj 2024 · 513 Background: The phase 3 KATHERINE (NCT01772472) study, met its primary endpoint by demonstrating significantly improved invasive disease-free survival with adjuvant T-DM1 compared to H in pts with residual invasive disease after neoadjuvant chemotherapy plus HER2-targeted therapy. PROs are reported here. Methods: Eligible … fairfield rawlins
T-DM1 Approval Expanded for HER2-Positive Breast Cancer
Webb5 nov. 2024 · Although TH was the standard of care for HER2 + disease at the time the TDM1/P and THP arms opened, pertuzumab was granted accelerated approval in the neoadjuvant setting during the enrollment period. Webb25 maj 2024 · Background: The Katherine trial has shown that adjuvant T-DM1 improved invasive disease free survival (iDFS) of patients with HER2+ breast cancer who did not achieve a pathological complete response (pCR) with trastuzumab-based neoadjuvant chemotherapy (NAC). However, some subgroups may benefit less from this treatment … Webb1 juli 2024 · The phase 3 KATHERINE trial demonstrated significantly improved invasive disease-free survival with adjuvant trastuzumab emtansine (T-DM1) versus … fairfield rd primary